Krista Davis Sells 1,000 Shares of ANI Pharmaceuticals (NASDAQ:ANIP) Stock

Key Points

• Krista Davis, Senior Vice President of ANI Pharmaceuticals, sold 1,000 shares of the company's stock for a total of $98,040, reducing her ownership by 1.63% to 60,186 shares.
• ANI Pharmaceuticals reported a 53.2% increase in revenue year-over-year, reaching $211.37 million, and surpassed analysts' earnings expectations by reporting $1.80 earnings per share.
• A number of brokerages have recently upgraded ANI Pharmaceuticals' stock rating, with Zacks Research and Wall Street Zen issuing a "strong-buy" rating, reflecting positive investor sentiment.

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) SVP Krista Davis sold 1,000 shares of ANI Pharmaceuticals stock in a transaction on Friday, September 19th. The shares were sold at an average price of $98.04, for a total value of $98,040.00. Following the completion of the transaction, the senior vice president owned 60,186 shares of the company's stock, valued at approximately $5,900,635.44. This trade represents a 1.63% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Krista Davis also recently made the following trade(s):

• On Friday, August 22nd, Krista Davis sold 1,763 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $91.10, for a total value of $160,609.30.

ANI Pharmaceuticals Stock Down 0.9%

NASDAQ:ANIP traded down $0.86 during midday trading on Monday, reaching $95.93. The company had a trading volume of 290,218 shares, compared to its average volume of 375,608. The firm has a market capitalization of $2.08 billion, a price-to-earnings ratio of -124.58 and a beta of 0.63. The stock's fifty day simple moving average is $82.71 and its 200-day simple moving average is $71.13. ANI Pharmaceuticals, Inc. has a 12-month low of $52.50 and a 12-month high of $99.50. The company has a current ratio of 2.54, a quick ratio of 1.96 and a debt-to-equity ratio of 1.39.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last released its earnings results on Friday, August 8th. The specialty pharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.42 by $0.38. The firm had revenue of $211.37 million during the quarter, compared to analyst estimates of $187.18 million. ANI Pharmaceuticals had a positive return on equity of 25.03% and a negative net margin of 1.37%.ANI Pharmaceuticals's revenue was up 53.2% compared to the same quarter last year. During the same period last year, the business posted $1.02 earnings per share. On average, sell-side analysts anticipate that ANI Pharmaceuticals, Inc. will post 3.86 earnings per share for the current fiscal year.

Hedge Funds Weigh In On ANI Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in the stock. Advisors Asset Management Inc. purchased a new stake in ANI Pharmaceuticals in the 1st quarter valued at approximately $28,000. Caitong International Asset Management Co. Ltd boosted its holdings in ANI Pharmaceuticals by 4,636.4% in the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 521 shares of the specialty pharmaceutical company's stock valued at $34,000 after purchasing an additional 510 shares in the last quarter. Newbridge Financial Services Group Inc. boosted its holdings in ANI Pharmaceuticals by 200.0% in the 2nd quarter. Newbridge Financial Services Group Inc. now owns 600 shares of the specialty pharmaceutical company's stock valued at $39,000 after purchasing an additional 400 shares in the last quarter. State of Wyoming purchased a new stake in ANI Pharmaceuticals in the 2nd quarter valued at approximately $50,000. Finally, National Bank of Canada FI purchased a new stake in ANI Pharmaceuticals in the 1st quarter valued at approximately $79,000. Institutional investors and hedge funds own 76.05% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on ANIP. Zacks Research raised ANI Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a report on Thursday, August 21st. Wall Street Zen raised ANI Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Saturday, August 16th. Piper Sandler reiterated an "overweight" rating and set a $94.00 target price on shares of ANI Pharmaceuticals in a research report on Friday, August 8th. Truist Financial lifted their target price on ANI Pharmaceuticals from $65.00 to $77.00 and gave the stock a "hold" rating in a research report on Monday, August 11th. Finally, Guggenheim lifted their target price on ANI Pharmaceuticals from $86.00 to $114.00 and gave the stock a "buy" rating in a research report on Monday, September 8th. Two equities research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Buy" and an average target price of $93.00.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.